The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
   Article
2. A 21st Century Evil: Immunopathology and New Therapies of COVID-19.Frontiers in immunology · 2020
   Review

Corrections and comments

• Commented on by
  A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.2020
• Comment on
  Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as